Pharmaceutical Executive-08-01-2012

Pharmaceutical Executive

Pharmaceutical Executive Digital Edition - August 2012

August 01, 2012

Issue PDF

0

0

Piramal Pivots for Growth

Country Report: Mexico

August 01, 2012

Country Report

0

0

Over ten years ago, the economic concept of the 'BRIC' countries-Brazil, Russia, India and China-was formed, and it's pretty much all we've heard about ever since. Yet earlier this year, the very same man who coined the term-Jim O'Neill, chief economist at Goldman Sachs-declared that by 2020 Mexico would be the seventh largest economy in the world, surpassing both India and Russia. Mexico belongs to one of four recently defined 'growth markets' alongside Indonesia, South Korea and Turkey. That certainly shakes things up a little for both outside observers and active local stakeholders in the economy.

Creallaborations: Pharma Starts Thinking Outside the Pill Box

August 01, 2012

Column

0

0

Creative non-pharmaceutical partnerships can offer innovators unique capabilities against the competition in a new era where challenges to market leadership are coming from every direction.

The Phrase that Plays

August 01, 2012

From the Editor

0

0

This month's feature by Ben Comer highlights what's behind the new Corporate Integrity Agreement (CIA) imposed on GSK by theHHS Office of Inspector-General to compensate for a long list of marketing and pricing malfeasances

Compliance Kulture: The Facts Behind GSK's CIA

August 01, 2012

Features

0

0

Big Pharma talks a lot about changing its business model to one that prioritizes quality and value over quantity and waste. While the healthcare "ecosystem" waits for pharma to grow into this model, government is delivering a comeuppance that actually puts it in the driver's seat and gaining the upper hand.

Data Exclusivity: Making the Case

August 01, 2012

Column

0

0

As the scope and complexity of registration information demanded by regulators increases, protection of that know-how has become a critical differentiator in the "go" or "no go" calculation on whether to invest in a new medicine.